Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2002

01-11-2002 | Original Article

Angiostatin potentiates cyclophosphamide treatment of metastatic disease

Authors: Helena J. Mauceri, Saraswathy Seetharam, Michael A. Beckett, Philip L. Schumm, Ann Koons, Vinay K. Gupta, James O. Park, Abdullah Manan, John Y. Lee, Anthony G. Montag, Donald W. Kufe, Ralph R. Weichselbaum

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2002

Login to get access
Metadata
Title
Angiostatin potentiates cyclophosphamide treatment of metastatic disease
Authors
Helena J. Mauceri
Saraswathy Seetharam
Michael A. Beckett
Philip L. Schumm
Ann Koons
Vinay K. Gupta
James O. Park
Abdullah Manan
John Y. Lee
Anthony G. Montag
Donald W. Kufe
Ralph R. Weichselbaum
Publication date
01-11-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0514-7

Other articles of this Issue 5/2002

Cancer Chemotherapy and Pharmacology 5/2002 Go to the issue

Original Article

High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer

Original Article

Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190

Original Article

Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

Original Article

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial

Original Article

Pharmacokinetics and organ distribution of N-methanocarbathymidine, a novel thymidine analog, in mice bearing tumors transduced with the herpes simplex thymidine kinase gene

Original Article

Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits